PLM-101

• UNSPSC Description:

  PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po)[1].

• Target Antigen:

  FLT3; RET

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/plm-101.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC1=CC2=C(C=C1)NC(/C2=C3NC4=CC=CC=C4C\3=N/OCCN5CCNCC5)=O

• Molecular Weight:

  407.44

• References & Citations:

  [1]Choi YJ, et al. PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia. Biomed Pharmacother. 2023 Sep;165:115066.. .

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported